President Joe Biden’s administration is considering a reassessment of Medicare Part B premiums after the drugmaker behind a new Alzheimer’s drug cut its price.
The administration announced in November 2021 that the monthly premium would rise by nearly $22 and attributed the rise in part to the potential use of Aduhelm, an Alzheimer’s drug from Biogen Inc.